Needham Reiterates Buy on Pliant Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a price target of $45.
September 27, 2023 | 8:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' stock rating has been reiterated as 'Buy' by Needham analyst Joseph Stringer, with a maintained price target of $45.
The reiteration of a 'Buy' rating by a reputable analyst like Joseph Stringer is a positive signal for investors. The maintained price target of $45 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100